Blasts 20 Percent or More of Bone Marrow Nucleated Cells
1 clinical trials · Condition
◉ Watch Blasts 20 Percent or More of Bone Marrow Nucleated Cells
| Record | Firm | Date |
|---|---|---|
| Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT04047641) | M.D. Anderson Cancer Center | 2019-10-22 |
Track Blasts 20 Percent or More of Bone Marrow Nucleated Cells automatically
Every clearance here is in the API, with alerts when new ones post.